A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio
1 other identifier
interventional
240
1 country
78
Brief Summary
A Phase 2, Randomized, Placebo-controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL-3007 in Combination with Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Jun 2025
78 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 23, 2025
CompletedFirst Submitted
Initial submission to the registry
June 30, 2025
CompletedFirst Posted
Study publicly available on registry
October 10, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 25, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
November 1, 2027
June 24, 2026
June 1, 2026
2 years
June 30, 2025
June 23, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change from baseline (CFB) in the area of artificial intelligence (AI)-based SD-OCT assessment of RPE lesion in the study eye
At month 12
Secondary Outcomes (9)
CFB in the area of AI-based OCT assessment of photoreceptor degeneration in the study eye
At month 12
Safety & tolerability based on adverse event (AE) reporting
At month 12
Safety as assessed by Best Corrected Visual Acuity (BCVA)
At Month 12
Change from baseline in Serum C3 level
At Month 12
CFB in RPE lesion area as assessed by FAF in the study eye
At month 12
- +4 more secondary outcomes
Study Arms (3)
Group 1 (APL-3007 Dose/Frequency 1 )
EXPERIMENTALAPL-3007 SC + pegcetacoplan (APL-2)
Group 2 (APL-3007 Dose/Frequency 2)
EXPERIMENTALAPL-3007 + pegcetacoplan (APL-2)
Group 3 (placebo)
PLACEBO COMPARATORPlacebo SC + pegcetacoplan (APL-2)
Interventions
Eligibility Criteria
You may qualify if:
- Aged ≥60 years
- Clinical diagnosis of GA of the macula secondary to AMD in one or both eyes, as determined by the investigator and confirmed by the reading center
- NL-BCVA of 50 letters or better using early treatment diabetic retinopathy study (ETDRS) charts (approximately 20/100 Snellen equivalent)
- Adequate clarity of ocular media, adequate pupillary dilation, and fixation to permit the collection of good quality images in the study eye as determined by the investigator
- Prior treatment for GA in the study eye using Syfovre at 6-8 weeks interval for at least 6 months but no more than 24 months. Participants will be included if the participant has had at least 2 Syfovre injections in the last 6 months before screening.
- The GA lesion in at least 1 eye (designated as the study eye) must meet the following criteria as determined by the central reading center's OCT based RPE assessment of imaging at screening:
- Total GA area must be ≥2.5 and ≤17.5 mm2 (1-7 disk areas \[DA\])
- If GA is multifocal, at least 1 focal lesion must be ≥1.25 mm2 (0.5 DA), with the overall aggregate area of GA as specified above in 7a
- The entire GA lesion must be completely visualized in the field of view of the OCT, with the GA RPE lesion border \>500 µm from the edge of the imaging window or any areas of peripapillary atrophy.
- Nonsubfoveal lesion with border of GA lesion not encroaching center of the fovea. Distance of GA RPE lesion from center of the fovea \>0 based on OCT imaging.
- Documented evidence of vaccination within 5 years prior to screening, or willing to initiate vaccinations at least 14 days prior to dosing against:
- Streptococcus pneumoniae (with a pneumococcal conjugate vaccine 15 \[PCV15\] or 20 \[PCV20\] or with pneumococcal polysaccharide vaccine 23 \[PPSV23\]),
- Haemophilus influenzae (type B) (with Hib vaccine),
- Neisseria meningitidis types A, C, W, and Y (with a quadrivalent meningococcal conjugate vaccine \[eg, Menactra or MenQuadfi\]), and
- Neisseria meningitidis type B (with a meningococcal serogroup B vaccine \[eg, Bexsero\])
- +5 more criteria
You may not qualify if:
- Uncontrolled, clinically relevant history of any gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiovascular, endocrinological, hematological or allergic disease, metabolic disorder, or cancer
- History or presence of hepatic cirrhosis or other liver disease that may increase the risk of drug-induced liver injury
- History or presence of systemic autoimmune disorders, with the exception of well controlled Hashimoto's thyroiditis
- History of allergy, hypersensitivity, or serious adverse reaction to siRNA therapy or related compounds, or allergy to any of the components of the study drug
- Clinically meaningful abnormalities on diagnostic and laboratory testing must be adjudicated by the sponsor's medical monitor and include:
- Cardiac
- Sustained resting heart rate outside of range of 40 to 100 beats/minute, or a heart rhythm that is not sinus rhythm, confirmed on repeat testing within a maximum of 30 minutes, at screening
- History or evidence of hereditary short QT syndrome
- Fridericia's corrected QT interval (QTcF) \>480 milliseconds, or the PR interval outside the range of 120 to 220 milliseconds, confirmed on repeat testing within a maximum of 30 minutes at screening
- Any clinically relevant features of acute coronary syndrome (unstable angina, myocardial infarction)
- Any other ECG parameters outside of age-adjusted normative range
- Hepatic
- AST or ALT \>1.3 × ULN
- Total bilirubin \>1.1 × ULN
- Any 2 LFTs \>1.1 × ULN
- +22 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (78)
Associated Retina Consultants (01065)
Gilbert, Arizona, 85297, United States
Barnet Dulaney Perkins Eye Center (01018)
Mesa, Arizona, 85206, United States
Associated Retina Consultants - Phoenix
Phoenix, Arizona, 85020, United States
Retinal Research Institute, LLC (01021)
Phoenix, Arizona, 85053, United States
Research Network Arizona
Scottsdale, Arizona, 46214, United States
California Retina Consultants (CRC) - Bakersfield Office
Bakersfield, California, 93309, United States
Retinal Diagnostic Center
Campbell, California, 95008, United States
The Retina Partners - Encino
Encino, California, 07003, United States
Retina Consultants of Orange County - Fullerton Office
Fullerton, California, 93825, United States
Salehi Retina Institute, Inc dba Retina Associate or Southern California (01034)
Huntington Beach, California, 92647, United States
Salehi Retina Institute, Inc. Dba Retina Associates of Southern California (01034)
Huntington Beach, California, 92647, United States
California Retina Consultants (01054)
Oxnard, California, 93036, United States
Retina Consultants San Diego
Poway, California, 92064, United States
Orange County Retina Medical Group
Santa Ana, California, 92705, United States
Retina Macula Institute
Torrance, California, 90503, United States
Bay Area Retina Associates - Walnut Creek
Walnut Creek, California, 94598, United States
Colorado Retina Associates, PLLC
Lakewood, Colorado, 80228, United States
Advanced Vision Research Institute
Longmont, Colorado, 80503, United States
Connecticut Eye Consultants, PC (01074)
Danbury, Connecticut, 06810, United States
ClearVista Clinical Research, LLC (01096)
Bayonet Point, Florida, 34667, United States
Advance Retina Institute
Bonita Springs, Florida, 34134, United States
Florida Retina Institute (01053)
Orlando, Florida, 32806, United States
Florida Retina Institute - Orlando (01053)
Orlando, Florida, 32806, United States
Retina Specialty Institute - Pensacola
Pensacola, Florida, 32503, United States
Eye Associates of Pinellas (01020)
Pinellas Park, Florida, 33782, United States
Retina Vitreous Associates of Florida (RVA) - Saint Petersburg
St. Petersburg, Florida, 33711, United States
Retina Vitreous Associates of Florida
Tampa, Florida, 33617, United States
Center for Retina and Macular Disease (01026)
Winter Haven, Florida, 33880, United States
Southeast Retina Center
Augusta, Georgia, 30909, United States
Illinois Retina Associates, S.C. - Oak Park (01061)
Oak Park, Illinois, 60304, United States
Midwest Eye Institute (01066)
Carmel, Indiana, 46032, United States
Vision Research Solutions
Indianapolis, Indiana, 21044, United States
Advancing Research International. LLC (01090)
Indianapolis, Indiana, 46214, United States
Retina Consultants P.C.
Indianapolis, Indiana, 46214, United States
Retina Associates New Orleans - Jefferson Parish Location
Metairie, Louisiana, 70001, United States
The Retina Care Center
Baltimore, Maryland, 21209, United States
The Retina Group of Washington (01089)
Chevy Chase, Maryland, 29902, United States
Cumberland Valley Retina Consultants (CVRC)
Hagerstown, Maryland, 21740, United States
Retina Specialists
Towson, Maryland, 21204, United States
Mississippi Retina Associates
Madison, Mississippi, 39110, United States
Envision Ocular, LLC (01027)
Bloomfield, New Jersey, 07003, United States
Mid Atlantic Retina (01039)
Cherry Hill, New Jersey, 08034, United States
NJ Retina (01031)
Edison, New Jersey, 08820, United States
NJ Retina (01030)
Toms River, New Jersey, 08755, United States
Vision Research Center Eye Associates of New Mexico (01023)
Albuquerque, New Mexico, 87109, United States
Long Island Vitreoretinal Consultants (01050)
Great Neck, New York, 11021, United States
Long Island Vitreoretinal Consultants - Westbury
Long Island City, New York, 11590, United States
Retina Assocaites of Cleveland, Inc (01048)
Cleveland, Ohio, 44122, United States
Retina Associates of Cleveland
Cleveland, Ohio, 44130, United States
Verum Research, LLC
Eugene, Oregon, 97401, United States
EyeHealth Northwest
Portland, Oregon, 97225, United States
EyeHealth Northwest (01006)
Portland, Oregon, 97228, United States
Cascade Medical Research Institute, LLC (01070)
Springfield, Oregon, 97477, United States
Eye Care Specialists
Kingston, Pennsylvania, 18704, United States
Mid Atlantic Retina - Philadelphia (01017)
Philadelphia, Pennsylvania, 19107, United States
Charleston Neuroscience Institute (01037)
Beaufort, South Carolina, 29902, United States
Retina Consultants of Carolina, PA (01073)
Greenville, South Carolina, 29605, United States
Charleston Neuroscience Institute LLC - Ladson
Ladson, South Carolina, 29456, United States
Charleston Neuroscience Institute, LLC - Mount Pleasant (01051)
Mt. Pleasant, South Carolina, 29464, United States
Ophthalmology Ltd. (01084)
Sioux Falls, South Dakota, 57108, United States
Tennessee Retina, PC (01063)
Nashville, Tennessee, 37203, United States
Retina Consultants of Texas - Abilene (01035)
Abilene, Texas, 79606, United States
Austin Retina Associates
Austin, Texas, 78705, United States
Retina Consultants of Texas - Bellaire (01067)
Bellaire, Texas, 77401, United States
Texas Retina Associates
Dallas, Texas, 75231, United States
Retina Consultants of Texas - Katy
Katy, Texas, 77494, United States
Valley Retina Institute- McAllen (01076)
McAllen, Texas, 78503, United States
Austin Retina Associates - Round Rock (01032)
Round Rock, Texas, 78681, United States
Retina Consultants of Texas - San Antonio Medical Center
San Antonio, Texas, 78240, United States
Austin Retina Associate (01046)
San Marcos, Texas, 78666, United States
Retina Consultants of Texas (01055)
Schertz, Texas, 78154, United States
Retina Center of Texas - Southlake
Southlake, Texas, 76092, United States
Retina Consultants of Texas - The Woodlands
The Woodlands, Texas, 73384, United States
Tyler Retina Consultants
Tyler, Texas, 75703, United States
Retina Associates of Utah (01052)
Salt Lake City, Utah, 84107, United States
Salt Lake Retina (01044)
West Jordan, Utah, 84088, United States
Piedmont Eye Center (01097)
Lynchburg, Virginia, 24502, United States
University of Wisconsin Health - University Station Clinic
Madison, Wisconsin, 53705, United States
MeSH Terms
Interventions
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- QUADRUPLE
- Who Masked
- PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 30, 2025
First Posted
October 10, 2025
Study Start
June 23, 2025
Primary Completion (Estimated)
June 25, 2027
Study Completion (Estimated)
November 1, 2027
Last Updated
June 24, 2026
Record last verified: 2026-06